ITG

ITM (Isotope Technologies Munich) is a leading radiopharmaceutical company dedicated to the development, production, and global supply of targeted diagnostic and therapeutic radiopharmaceuticals and radioisotopes for cancer treatment. The company is best known for its high-purity non-carrier-added (n.c.a.) Lutetium-177 (EndolucinBeta), which is a critical component in several approved and investigational radioligand therapies. ITM operates an extensive supply network and maintains a robust internal pipeline, including its lead candidate ITM-11 for the treatment of neuroendocrine tumors. Headquartered in Garching, Germany, the company collaborates with major pharmaceutical players and academic institutions to advance the field of precision oncology.